Nerviano Medical Sciences
Sidney Dung 董欣宜 has extensive work experience in various leadership roles. Currently, they serve as the Chief Operating Officer at Nerviano Medical Sciences - Part of NMS Group, where they focus on research and development to bring transformative oncology drugs to patients. Sidney Dung is responsible for partnering with the CEO and executive team to define and implement the company's strategy, as well as scaling the organization. Sidney also serves as a Board Member for SIMIS SRL. Prior to their current roles, they worked as the Chief Operating Officer and Chief of Staff/Member of the Executive Leadership Team at NMS Group. Their responsibilities included strategic planning, operational execution, capital management, and investor relations. Sidney also has experience in brand and corporate communications, employee branding, and CSR as the Head of Brand at NMS Group. Before joining NMS, they held positions in external and investor relations, communications, and business development at Share'ngo - C.S. Group S.p.A., Dagong Europe Credit Rating, CNH Industrial, and Iveco S.p.A. Sidney began their career as a market analyst at the Taipei Representative Office in Italy, Economic Division. Sidney Dung also worked as a senior consultant and area manager for Asia at Lord Cultural Resources and as a marketing coordinator at Swatch Group.
Sidney Dung 董欣宜 completed a Master of Business Administration (MBA) with a focus on Marketing and Arts and Media Administration at the Schulich School of Business - York University from 1999 to 2001. Prior to that, Sidney obtained a Bachelor of Arts degree in Library Science and Business Administration from the National Taiwan University between 1994 and 1997.
This person is not in any offices
Nerviano Medical Sciences
Nerviano Medical Sciences is part of NMS Group and it is focused on the discovery and early development of oncology drugs. Our business model is to partner our drugs at late preclinical or early clinical stage for full development and commercialization. Our mission is to pursue innovative therapeutic approaches in Oncology, discovering and developing molecules with novel mechanisms of action, for the advancement of personalized care of cancer patients. An experienced and lean management team leads a highly skilled staff of professionals with international experience and a broad range of expertise in R&D, combining the flexibility of a biotech with the quality standards of a big pharma.